Clomipramine
As of the edition of 20 October 2026, Clomipramine is a small molecule: marketed, first approved in 1967 (ES); acts on SLC6A4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1989
- Kind
- Small molecule
- Brand name
- Anafranil
- First approved
- 1 June 1967 (ES)
- Approvals on record
- 6 in 4 regions
- Holder of the most recent approval
- Specgx; 4 holders in all
- Registered trials
- 6, 1 stopped early
- Disease areas
- Mental health; Nervous system; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC6A4 | Sodium-dependent serotonin transporter | P31645 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 1 | 0 | 0 |
| Phase 3 | 2 | 1 | 0 | 1 |
| All trials | 6 |